Avidity Biosciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Avidity Biosciences, Inc.

Avidity Biosciences, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ under the ticker RNA in the United States. Headquartered in San Diego, California, the company was founded in 2012 as Avidity NanoMedicines LLC and later converted into Avidity Biosciences, Inc. in 2019. Avidity is positioned as a next-generation RNA therapeutics company, built around its proprietary Antibody Oligonucleotide Conjugate (AOC) platform, which is designed to deliver oligonucleotides to hard-to-reach tissues, especially muscle. The company’s business model is centered on research, clinical development, and eventual commercialization of precision medicines for rare neuromuscular diseases. Avidity’s core pipeline includes three clinical programs targeting three distinct rare disorders: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Its lead product candidate, delpacibart etedesiran (del-desiran, AOC 1001), is being developed for DM1; delpacibart braxlosiran (del-brax) targets FSHD; and delpacibart zotadirsen (del-zota) is advancing in DMD. Beyond muscle biology, the company has also stated that it is expanding the reach of AOCs into additional therapeutic areas through internal discovery and strategic partnerships. From a competitive standpoint, Avidity operates in a highly capital-intensive specialty biotechnology segment where value creation depends on clinical validation, delivery precision, and the ability to translate late-stage data into regulatory approvals. Its differentiation lies in its delivery technology: rather than treating RNA therapeutics as a broad platform alone, Avidity is trying to solve one of the field’s key limitations by achieving more effective tissue targeting. That makes the company a potentially important player in RNA medicines, but also one with meaningful binary risk tied to clinical outcomes, regulatory decisions, and execution on commercialization. Recent developments highlight both clinical progress and an increasingly advanced pipeline. In 2025, Avidity said it had aligned with the FDA on accelerated and full approval pathways for del-brax in FSHD, reported positive topline Phase 1/2 FORTITUDE data, and initiated a global confirmatory Phase 3 study. The company also said it remained on track to submit the BLA for del-zota in DMD at year-end 2025, with a goal of multiple regulatory submissions over a 12-month period. Combined with management’s commentary around a cash runway that supports development and launch preparation, these milestones reinforce Avidity’s profile as a high-growth health-care stock on the NASDAQ that investors will monitor for execution, clinical data, and regulatory catalysts.